CompanyGraph
Perspective Therapeutics Inc.
CATX · NYSE Arca · United States
perspectivetherapeutics.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $618,000, lower than 95% of all stocks globally
- PositionOperating margin is -37211.8%, lower than 95% of its Medical Devices peers (median 8.1%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
341.00MUSDvs all stocks (USD)
Revenue (TTM)
618.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Medical Devices peers
Beta
1.75xvs all stocks
52-Week Change
-30.63%vs all stocks
Market Capitalization
341.00MUSDvs all stocks (USD)
Enterprise Value
100.53MUSDvs all stocks (USD)
Forward P/E
-2.84xvs Medical Devices peers
Price to Book (MRQ)
1.06xvs Medical Devices peers
Enterprise to Revenue
162.67xvs Medical Devices peers
Enterprise to EBITDA
-0.8640xvs Medical Devices peers
Profit Margin
0.00%vs Medical Devices peers
Return on Assets (TTM)
-20.27%vs Medical Devices peers
Return on Equity (TTM)
-35.33%vs Medical Devices peers
Revenue (TTM)
618.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0080USDUpdated Jul 18, 2026Quarterly Revenue Growth
-77.80%vs Medical Devices peers
Gross Profit (TTM)
-90.64MUSDvs all stocks (USD)
EBITDA (TTM)
-116.38MUSDvs all stocks (USD)
Net Income (TTM)
-111.65MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-92.37MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-58.78MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-113.56MUSDvs all stocks (USD)
Pre-tax Income
-104.43MUSDFY2025 · Dec 31, 2025Income Tax Expense
-793.00KUSDFY2025 · Dec 31, 2025Net Income
-103.12MUSDFY2025 · Dec 31, 2025EBIT
-104.05MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-100.80MUSDFY2025 · Dec 31, 2025Research & Development
84.22MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
30.23MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-884.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.11MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
376.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.40USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.40USDFY2025 · Dec 31, 2025Basic Shares Outstanding
73.81MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
73.81MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-103.12MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-92.65MUSDFY2025 · Dec 31, 2025Free Cash Flow
-105.39MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
30.63MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-103.12MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.25MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-793.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.97MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-32.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
147.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.07MUSDFY2025 · Dec 31, 2025Capital Expenditures
-12.75MUSDFY2025 · Dec 31, 2025Purchase of Investments
-119.84MUSDFY2025 · Dec 31, 2025Sale of Investments
173.95MUSDFY2025 · Dec 31, 2025Other Investing Activity
-135.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
41.23MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-52.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
9.93MUSDFY2025 · Dec 31, 2025Shares Outstanding
114.02MSharesUpdated Jul 18, 2026Float Shares
66.42MSharesUpdated Jul 18, 2026Shares Short
22.72MSharesUpdated Jul 18, 2026Short Ratio
9.97daysvs all stocks
Short % of Shares Outstanding
23.80%vs all stocks
% Held by Insiders
10.81%vs all stocks
% Held by Institutions
77.43%vs all stocks
Total Cash (MRQ)
270.93MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.38USDUpdated Jul 18, 2026Total Debt (MRQ)
4.23MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0122xvs Medical Devices peers
Current Ratio (MRQ)
8.74xvs Medical Devices peers
Book Value per Share (MRQ)
3.05USDUpdated Jul 18, 2026Total Assets
266.97MUSDvs all stocks (USD)
Total Current Assets
148.39MUSDFY2025 · Dec 31, 2025Total Liabilities
59.94MUSDFY2025 · Dec 31, 2025Total Non-current Assets
118.58MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
31.26MUSDFY2025 · Dec 31, 2025Total Current Liabilities
28.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
30.63MUSDFY2025 · Dec 31, 2025Other Short-term Investments
114.11MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.00KUSDFY2025 · Dec 31, 2025Accounts Payable
20.51MUSDFY2025 · Dec 31, 2025Short-term Debt
679.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
2.57MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
386.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
74.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-334.84MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
207.03MUSDvs all stocks (USD)
52-Week Low
1.96USDUpdated Jul 18, 202652-Week High
6.16USDUpdated Jul 18, 202652-Week Change
-30.63%vs all stocks
Beta
1.75xvs all stocks
50-Day MA
3.44USDUpdated Jul 18, 2026200-Day MA
3.59USDUpdated Jul 18, 2026Avg 10-Day Volume
2.26MSharesUpdated Jul 18, 2026Avg 30-Day Volume
2.30MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.41USDUpdated Jul 18, 2026Other Income / Expense
1.40MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -37211.8%, lower than 95% of its Medical Devices peers (median 8.1%)Significant
Operating margin: -372.118Industry median: 0.08Industry P5: -0.73Peers compared: 102
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 8.74Altman Z-Score: 0.91
Financial Health
Altman Z-Score 0.91: distress zoneCritical
Altman Z-Score: 0.91
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $618,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 618,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Organogenesis Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Xinguang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Spire Global Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Ars Pharmaceuticals Inc
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Sarepta Therapeutics Inc.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated